Description du projet
Des anticorps thérapeutiques pour les chiens
Posséder un animal de compagnie est de plus en plus courant dans l’UE, et le marché mondial de la santé de ces animaux représente plus de 10 milliards d’euros. Les thérapies actuelles pour soigner les maladies inflammatoires chroniques, y compris la maladie inflammatoire chronique de l’intestin, sont onéreuses et inefficaces, entraînant souvent l’euthanasie de l’animal. Le projet CAESAR, financé par l’UE, fournit un soutien à l’entreprise allemande de biotechnologie Adivo dans le but de développer des anticorps thérapeutiques pour les chiens afin de traiter le cancer et l’inflammation chronique, avec le potentiel de s’étendre au développement de produits thérapeutiques destinés à d’autres espèces à l’avenir. L’entreprise a déjà mis au point la première bibliothèque d’expression phagique canine de son genre qui permettrait de générer des anticorps thérapeutiques pour les chiens, alors que le premier objectif consiste à synthétiser des anticorps thérapeutiques spécifiques innés pour le traitement de la maladie inflammatoire chronique de l’intestin.
Objectif
Chronic inflammatory diseases in pets such as Inflammatory Bowel Diseases (IBD) are poorly managed causing emotional and financial distress to pet owners. Current therapies are ineffective - they do not relieve pet suffering and lead to the animal being put down. Therapies are also expensive with costs up to €400/month. Antibody therapy for such conditions has long been used in human medicine but has not been sufficiently developed for veterinary medicine and causes an immunogenic response as the antibodies are not species specific. Antibodies need to be adapted which is expensive and causes severe side effects making them an untenable solution at present. Pet ownership in the EU has been on the increase (up by 2million pets since 2016) due to demographic shifts and a greater reliance on pets as companions. The global animal health market is worth > €29Bn growing at a CAGR of 6% with pet health making up 40% of the market. Pet owners spend €3k - €5k/ year on their pet’s health and are willing to pay to ease pet suffering. adivo is a German biotech company specializing in generating species-specific therapeutic antibodies for companion animals. adivo was founded in 2018. The adivo-team aims to address medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in future. adivo has developed CAESAR, the first of a kind synthetic canine phage-display library to generate therapeutic antibodies for dogs. We have developed a complete library from which we can synthesize therapeutic antibodies native to treat IBD. Our solution will overcome the challenges of current therapies and provide an affordable, scalable solution for effective antibody therapy for pets which has been demonstrated in human medicine. We expect to generate out-licensing revenue ≥€15M when we launch the product before royalties and hire 12 people.
Champ scientifique
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.
CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- agricultural sciencesanimal and dairy sciencedomestic animals
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
82152 PLANEGG
Allemagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.